Recombinant Human PD-1 Fc Chimera Protein, CF
R&D Systems, Inc. a Bio-Techne Brand
Key Product Details
Source: | NS0 |
Accession #: | Q15116.3 |
Structure / Form: | Disulfide-linked homodimer |
Applications: | Binding Activity |
Customers also Viewed
Customers also Purchased
Citations for Recombinant Human PD-1 Fc Chimera Protein, CF (30)
Citations are publications that use Bio-Techne products. Selected citations for Recombinant Human PD-1 Fc Chimera Protein, CF include:
-
Species: Human
Sample Types: Recombinant Proteins
Applications: BioassayR Zhang et al. (2022), D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1 Proceedings of the National Academy of Sciences of the United States of America, 119(8).
PMID: 35181605 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayN Erlichman et al. (2022), Tumor Cell-Autonomous Pro-Metastatic Activities of PD-L1 in Human Breast Cancer Are Mediated by PD-L1-S283 and Chemokine Axes Cancers, 14(4).
PMID: 35205789 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayQ Wang et al. (2022), Regulation of PD-L1 through direct binding of cholesterol to CRAC motifs Science Advances, 8(34):eabq4722.
PMID: 36026448 -
Species: Mouse
Sample Types: In Vivo
Applications: In VivoT Phakham et al. (2022), Highly efficient hybridoma generation and screening strategy for anti-PD-1 monoclonal antibody development Scientific Reports, 12(1):17792.
PMID: 36273231 -
Species: Human
Sample Types: Phage
Applications: BioassaySS Ghaderi et al. (2022), Development of a human phage display-derived anti-PD-1 scFv antibody: an attractive tool for immune checkpoint therapy BMC biotechnology, 22(1):22.
PMID: 35996120 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayC Vetrei et al. (2021), Immunomodulatory mAbs as Tools to Investigate on Cis-Interaction of PD-1/PD-L1 on Tumor Cells and to Set Up Methods for Early Screening of Safe and Potent Combinatorial Treatments Cancers, 13(12).
PMID: 34201082 -
Species: Human
Sample Types: Whole Cells
Applications: Binding AssayY Ren et al. (2021), TRAPPC4 regulates the intracellular trafficking of PD-L1 and antitumor immunity Nature Communications, 12(1):5405.
PMID: 34518538 -
Species: Human
Sample Types: Whole Cells
Applications: Fluorescence AssayJJ Park et al. (2021), Checkpoint inhibition through small molecule-induced internalization of programmed death-ligand 1 Nature Communications, 12(1):1222.
PMID: 33619272 -
Species: Human
Sample Types: Protein
Applications: BioassayCJ Edwards et al. (2021), The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity British Journal of Cancer, 0(0).
PMID: 34969998 -
Species: Human
Sample Types: Cell Culture Supernates
Applications: ELISA CaptureN Silva-Pili et al. (2020), Long-Term Systemic Expression of a Novel PD-1 Blocking Nanobody from an AAV Vector Provides Antitumor Activity without Toxicity Biomedicines, 8(12).
PMID: 33276580 -
Species: Human
Sample Types: Whole Cells
Applications: Cell CultureC Li et al. (2020), Repurposing screen identifies Amlodipine as an inducer of PD-L1 degradation and antitumor immunity Oncogene, 0(0).
PMID: 33323966 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayD Zhu et al. (2020), Deubiquitinating enzyme OTUB1 promotes cancer cell immunosuppression via preventing ER-associated degradation of immune checkpoint protein PD-L1 Cell Death and Differentiation, 0(0).
PMID: 33328570 -
Species: Human
Sample Types: Whole Cells
Applications: ICCN Zhang et al. (2019), SA-49, a novel aloperine derivative, induces MITF-dependent lysosomal degradation of PD-L1 EBioMedicine, 0(0).
PMID: 30711516 -
Species: Human
Sample Types: Whole Cells
Applications: Flow CytometryW Wang et al. (2019), Upregulation of PD-L1 via HMGB1-activated IRF3 and NF-kB contributes to UV radiation-induced immune suppression Cancer Res., 0(0).
PMID: 30737234 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayM Passariell et al. (2019), Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling Sci Rep, 9(1):13125.
PMID: 31511565 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayM Liberelle et al. (2019), MUC4-ErbB2 Oncogenic Complex: Binding studies using Microscale Thermophoresis Sci Rep, 9(1):16678.
PMID: 31723153 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayB Shao et al. (2018), Deglycosylation of PD-L1 by 2-deoxyglucose reverses PARP inhibitor-induced immunosuppression in triple-negative breast cancer Am J Cancer Res, 8(9):1837-1846.
PMID: 30323975 -
Species: Human
Sample Types: Plasma
Applications: ELISA (Capture)A Osa et al. (2018), Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients JCI Insight, 3(19).
PMID: 30282824 -
Species: Human
Sample Types: Whole Cells
Applications: Flow CytometryH Wang et al. (2018), HIP1R targets PD-L1 to lysosomal degradation to alter T cell-mediated cytotoxicity Nat. Chem. Biol., 0(0).
PMID: 30397328 -
Species: Human
Sample Types: Whole Cells
Applications: ICCCW Li et al. (2018), Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1 Cancer Cell, 33(2):187-201.e10.
PMID: 29438695 -
Sample Types: Protein
Applications: BioassaySamit Chatterjee (2016), Rapid PD-L1 detection in tumors with PET using a highly specific peptide Biochem. Biophys. Res. Commun, 0(0).
PMID: 28025143 -
Species: Human
Sample Types: Whole Cells
Applications: Bioassay(2016), Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity Nat Commun, 7(0):12632.
PMID: 27572267 -
Species: Human
Sample Types: Whole Cells
Applications: Bioassay(2016), Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers Nature, 0(0).
PMID: 27281199 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayYang Y et al. (2015), B7-H1 enhances proliferation ability of gastric cancer stem-like cells as a receptor. Oncol Lett, 9(4):1833-1838.
PMID: 25789052 -
Species: Human
Sample Types: Serum
Applications: ELISA (Standard)Melendreras S et al. (2014), Soluble co-signaling molecules predict long-term graft outcome in kidney-transplanted patients. PLoS ONE, 9(12):e113396.
PMID: 25478957 -
Species: Human
Sample Types: Whole Cells
Applications: BioassaySteidl C et al. (2011), MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature, 471(7338):377-81.
PMID: 21368758 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayKim YS et al. (2008), Cross-linking of B7-H1 on EBV-transformed B cells induces apoptosis through reactive oxygen species production, JNK signaling activation, and fasL expression. J. Immunol., 181(9):6158-69.
PMID: 18941206 -
Species: N/A
Sample Types: N/A
Applications: ELISA (Standard)Sakthivel P et al. (2007), Programmed Death-1: from gene to protein in autoimmune human myasthenia gravis. J. Neuroimmunol., 193(1):149-55.
PMID: 18037500 -
Wan B et al. (2006), Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. J. Immunol., 177(12):8844-50.
PMID: 17142787 -
Species: Human
Sample Types: Serum
Applications: ELISA (Capture)Brahmer J et al. (0), Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Onco28(19):3167-75.
PMID: 20516446
There are no citations that match your criteria.
Customer Reviews for Recombinant Human PD-1 Fc Chimera Protein, CF (9)
Customer Images
-
Application: In vitro bioactivity in cell cultureVerified Customer | Posted 06/26/2020
-
Application: Binding assay/Protein-protein interactionVerified Customer | Posted 01/15/2020
-
Application: Binding assay/Protein-protein interactionVerified Customer | Posted 01/12/2020
-
Application: Binding assay/Protein-protein interactionVerified Customer | Posted 11/22/2019Cells expressing a negative control (left) or hPD-L1 mCherry (right) were treated with 0.25 ug of hPD-1 hIgG1. Cells were analyzed by flow cytometry with binding detected using an anti-human 488 secondary antibody.
-
Application: Binding assay/Protein-protein interactionVerified Customer | Posted 08/20/2018
-
Application: Binding assay/Protein-protein interactionVerified Customer | Posted 12/08/2017
-
Application: Binding assay/Protein-protein interactionVerified Customer | Posted 11/03/2017
-
Verified Customer | Posted 04/21/2017
-
Application: Binding assay/Protein-protein interactionVerified Customer | Posted 07/08/2016Sorry that I just rate the catalog based on my alike recombinant PD1 peptide. I have one question for the peptide. Owing the Ig like peptide with Fc fragment. So when we detect it binding to PDL1 on cell assay, it is difficult to get definite conclusion if it is PDL1 binding or others.My protocol is as below:-Cells with PDL1 high level was treated by PD1 like peptide,-4degree 1hr-collected and lysis-WB by anti-IgG to Fc recognization.Result: weak signal. you don't know if it is non-specific bindingBio-Techne ResponseThank you for reviewing our product. We are sorry to hear that this antibody did not perform as expected. We have been in touch with the customer to resolve this issue according to our Product Guarantee and to the customer’s satisfaction.
There are no reviews that match your criteria.
FAQs for Recombinant Human PD-1 Fc Chimera Protein, CF
-
The vial is supposed to contain lyophilized protein but it appears to be empty. Is there anything in it?
Pellets can be dislodged during shipping and become disbursed on the vial wall and in the cap. Centrifuge or tap the vial on the benchtop to return this material to the vial bottom. If this does not reveal a pellet, closely inspect the cone of the vial. Some pellets appear as only a tiny amount of material or as a transparent film due to the original buffer formulation. This is a normal appearance for many proteins. For example, if the product is originally lyophilized from a solvent such as acetonitrile or ethanol, and supplied carrier-free, you may not be able to detect the pellet with the naked eye. This does not mean the vial is empty. Reconstitute the vial as directed. After reconstitution, protein concentration can be tested with a spectrophotometer.
-
What is the recommended method for reconstitution of a lyophilized protein or antibody?
Unless more specific directions are on the Certificate of Analysis provided with the product, we suggest the following procedure to ensure optimal recovery: 1. Allow the vial and reconstitution buffer to equilibrate to room temperature. 2. Briefly centrifuge the vial to ensure that all lyophiliate is collected at the bottom of the vial. 3. Add the amount of buffer required to achieve the concentration recommended on the product insert. 4. Allow the vial to reconstitute for 15-30 minutes at room temperature with gentle agitation, like on a rocker platform or rotating by hand. Avoid vigorous shaking that can cause foaming and protein denaturation. 5. Aliquot into volumes greater than 20 μL and store as indicated on the product insert. If the vial exhibits flakes or particulates, mix the product for a couple of hours at room temperature and then at 4oC overnight. Contact Technical Service if product does not go into solution.
-
Are R&D Systems recombinant proteins and antibodies sterile?
Although the vials are bottled using aseptic techniques, heat-treated vials, and sterile stock solutions, they are not considered or guaranteed to be sterile. If sterile material is needed for an experiment, the material can be filtered through a 0.2 micron filter designed for use with biological fluids.